A Phase 2 interventional study of GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E and Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A) in Respiratory Disorders, sponsored by GlaxoSmithKline. Completed at 14 sites in 5 countries. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-23.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Respiration Disorders by GlaxoSmithKline — none open to participants now, 1 under way, 1 of them phase 3. Respiration Disorders · GlaxoSmithKline.
Among the 22 studies in Respiration Disorders by GlaxoSmithKline, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 2, and was the 19th registered.
359 studies on the registry are indexed under Respiration Disorders; 64 are open to participants now.
Browse Respiration Disorders studies →None of the 22 studies in Respiration Disorders by GlaxoSmithKline is open now. The open studies under Respiration Disorders, anywhere →
Of the 45 Respiration Disorders studies recruiting now, 27 (60%) set no upper age limit and 13 (29%) stop at 75 or younger; 15 take children under 18; 21 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2019.
This study's enrollment of 541 is above the median of 69 across 216 interventional studies indexed under Respiration Disorders.
Median enrollment 120 across the 19 interventional studies, 2,116 across the 3 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Respiration Disorders by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01.
The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered sequentially after Shingrix vaccine and to compare to the immunogenicity of NTHi-Mcat vaccine administered alone. This study will also provide information regarding whether a specific time period is required between the administration of these two different vaccines containing the same adjuvant- AS01 components.
The population of this study will include healthy smokers and ex-smokers of 50 to 80 years of age which will be used as a proxy for the COPD population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The investigator will exercise his/her medical and scientific judgement in deciding whether other diseases have an origin and thus meet the exclusion criteria.
Note: For M59 adjuvanted flu vaccine and for any vaccine containing novel adjuvant refer to exclusion criteria below.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.
Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E · Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.
Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E · Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.
Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E · Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.
Biological: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.
Biological: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
Anti-Protein D (PD), Anti-Protein E (PE), Anti-type IV Pili Subunit (PilA) and Anti-ubiquitous Surface Protein A2 of Moraxella Catarrhalis (UspA2) Adjusted Geometric Mean Concentrations (GMCs), One-month Post Dose-2 of NTHi-Mcat Vaccine
Antibody concentrations as measured by ELISA (Enzyme-linked immunosorbent assay) and expressed as adjusted (ANCOVA model) GMCs in ELISA units per milliliter (EU/mL). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively. The ANCOVA model includes study group, smoking status (current or former), age category (50-59, 60-69, 70-80 years of age) and center as factors and the antibody concentration before Dose 1 as covariate. As per protocol set (PPS) sample size was not met in Sh_NTHi_Mcat_3 and Sh_NTHi-Mcat_6 groups then timeframe was adapted as follows: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181 in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)
Time frame: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181, in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)
Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, Before First NTHi-Mcat Vaccine
GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations)
Time frame: Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 for Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 for NTHi-Mcat group)
Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibody Concentrations in Terms of GMCs, One-month Post Dose-2 of NTHi-Mcat Vaccine
GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations) before the first dose of NTHi-Mcat vaccine
Time frame: At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)
Percentage of Seropositive Subjects for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies Before First NTHi-Mcat Vaccine
A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI is defined using the assay lower limit of quantification (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively
Time frame: Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)
Percentage of Subjects Seropositive for Anti-PD, Anti-PE, Anti-PilA, Anti-UspA2 Antibodies, One-month Post Dose-2 of NTHi-Mcat Vaccine
A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI are defined using the assay (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively
Time frame: At one month after the second dose of NTHi-Mcat vaccine (Day 181, 241, 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)
Frequency of Specific Cluster of Differentiation 4 (CD4+) T-cells Against NTHi and Mcat Antigens for Evaluation of Cell-mediated Immune (CMI) Response, Before First Dose of NTHi-Mcat Vaccine
Frequency of specific CD4+ T-cells was measured by flow cytometry intracellular cytokine staining (ICS) expressing at least 2 different markers among CD40 Ligand (CD40L), interleukin (IL)-2, IL-13, IL-17, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), upon in vitro stimulation
Time frame: Before the first dose of NTHi-Mcat vaccine (Day 91, Day 151 and Day 241 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 1 in the NTHi-Mcat group)
Frequency of CD4+ T-cells Against NTHi and Mcat Antigens for Evaluation of CMI Response, at One-month Post Dose 2 of NTHi-Mcat Vaccine
Frequency of specific CD4+ T-cells was measured by flow cytometry ICS expressing at least 2 different markers among CD40L, IL-2, IL-13, IL-17, TNF-α and IFN-γ, upon in vitro stimulation
Time frame: At one month after second dose of NTHi-Mcat vaccine (Day 181, Day 241 and Day 331 in the Sh_NTHi-Mcat_1, Sh_NTHi-Mcat_3 and Sh_NTHi-Mcat_6 group, respectively, and Day 91 in the NTHi-Mcat group)
Percentage of Subjects With Reported Solicited Local Adverse Event (AE)
The percentage of subjects with at least one local solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed local symptoms were pain, redness and swelling. Any local injection site redness/swelling is scored as follows: diameter \>=20 milli-meters
Time frame: During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine
Percentage of Subjects With Reported Solicited General AE
The percentage of subjects with at least one general solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed solicited general symptoms were Fatigue, Gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Chills and Fever (oral cavity or axillary route - temperature equal or higher than \[\>=\] 37.5 degrees Celsius \[°C\])
Time frame: During the 7-day follow-up period (i.e. day of vaccination and 6 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine
Percentage of Subjects With Any Unsolicited AE
An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. The percentage of subjects with at least one unsolicited AE, regardless of intensity or relationship to vaccination, during the 30-day follow-up period after any NTHi-Mcat vaccine dose are reported for each group. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event
Time frame: During the 30-day follow-up period (i.e. day of vaccination and 29 subsequent days) after Dose 1 and after Dose 2 of NTHi-Mcat vaccine
Percentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 001
The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 1 up to and including Day 331, were reported for each group An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician
Time frame: From Day 1 up to and including Day 331 (Epoch 001)
Percentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 001
pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From Day 1 up to and including Day 331 (Epoch 001)
Percentage of Subjects With Any SAE During Epoch 002
The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 332 up to and including Day 661, are reported for each group. An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, requires hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician.
Time frame: From Day 332 up to and including Day 661 (Epoch 002)
Percentage of Subjects With Any pIMD's During Epoch 002
pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology
Time frame: From Day 332 up to and including Day 661 (Epoch 002)
| Milestone | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group |
|---|---|---|---|---|---|
| Started | 134 | 134 | 122 | 135 | 16 |
| Completed | 129 | 129 | 118 | 128 | 2 |
| Not completed | 5 | 5 | 4 | 7 | 14 |
| Withdrew: Adverse event | 0 | 2 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 4 | 8 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Unsolicited non-serious advers event | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Solicited adverse event | 0 | 1 | 0 | 0 | 0 |
Antibody concentrations as measured by ELISA (Enzyme-linked immunosorbent assay) and expressed as adjusted (ANCOVA model) GMCs in ELISA units per milliliter (EU/mL). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively. The ANCOVA model includes study group, smoking status (current or former), age category (50-59, 60-69, 70-80 years of age) and center as factors and the antibody concentration before Dose 1 as covariate. As per protocol set (PPS) sample size was not met in Sh_NTHi_Mcat_3 and Sh_NTHi-Mcat_6 groups then timeframe was adapted as follows: At 1 month after dose 2 of NTHi-Mcat vaccine (Day 181 in Sh_NTHi-Mcat_1 group and Day 91 in NTHi-Mcat group)
| EU/mL | Sh_NTHi-Mcat_1 Group | NTHi-Mcat Group |
|---|---|---|
| Anti-PD | 1402.804 (1139.194 to 1727.414) | 1489.531 (1203.846 to 1843.014) |
| Anti-PE | 6234.827 (5053.049 to 7692.992) | 7032.52 (5666.105 to 8728.452) |
| Anti-PilA | 1244.373 (963.063 to 1607.854) | 1089.799 (840.246 to 1413.47) |
| Anti-UspA2 | 1022.961 (894.403 to 1169.998) | 941.45 (820.993 to 1079.58) |
GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations)
| EU/mL | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| Anti-PD | 94.7 (86.2 to 104.1) | 105.1 (89.8 to 123) | 95.6 (84.5 to 108.3) | 105.3 (93.4 to 118.6) |
| Anti-PE | 22 (18 to 26.9) | 21.2 (17.6 to 25.4) | 18.6 (14.3 to 24.2) | 23.9 (19.8 to 28.9) |
| Anti-PilA | 7.8 (6.6 to 9.3) | 10.5 (8.2 to 13.5) | 9.7 (7.5 to 12.6) | 9.1 (7.5 to 11) |
| Anti-UspA2 | 352.4 (292.5 to 424.7) | 343 (286.3 to 411) | 440.3 (343.5 to 564.5) | 521.4 (441 to 616.3) |
GMCs and their 95% CI for each of the antibodies, as measured by ELISA, were calculated (the GMCs were computed by taking the Anti-log of the mean of the log concentration transformations) before the first dose of NTHi-Mcat vaccine
| EU/mL | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| Anti-PD | 1496.7 (1272.7 to 1760.1) | 1504 (1209.9 to 1869.6) | 1539 (1277.3 to 1854.2) | 1683.5 (1434.5 to 1975.5) |
| Anti-PE | 5911.8 (5121.3 to 6824.3) | 5920.8 (4868.4 to 7200.8) | 6048.5 (4943.3 to 7400.8) | 6562.4 (5660.9 to 7607.5) |
| Anti-PilA | 1089.3 (910.3 to 1303.4) | 1030.6 (839.4 to 1265.3) | 1114.7 (864.9 to 1436.6) | 999.3 (830.3 to 1202.7) |
| Anti-UspA2 | 926.8 (796.6 to 1078.4) | 942.2 (819.6 to 1083.2) | 1289.2 (1062.5 to 1564.5) | 1066.4 (946.6 to 1201.4) |
A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI is defined using the assay lower limit of quantification (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| Anti-PD | 16.9 (10.7 to 25) | 20 (12.5 to 29.5) | 19.2 (10.9 to 30.1) | 21.8 (14.9 to 30.1) |
| Anti-PE | 57.6 (48.2 to 66.7) | 63.5 (53.1 to 73.1) | 50.7 (38.7 to 62.6) | 61.8 (52.6 to 70.4) |
| Anti-PilA | 38.1 (29.4 to 47.5) | 49 (38.6 to 59.4) | 47.9 (36.1 to 60) | 43.5 (34.7 to 52.7) |
| Anti-UspA2 | 100 (96.9 to 100) | 100 (96.2 to 100) | 100 (95.1 to 100) | 100 (97.1 to 100) |
A seropositive subject is defined as a subject whose Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibody concentrations are greater than or equal to the assay cut-off value. Seropositivity rates with 95% CI are defined using the assay (LLOQ). Cut-off value for the assay is 153, 16, 8 and 28 EU/mL for Anti-PD, Anti-PE, Anti-PilA and Anti-UspA2 antibodies respectively
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| Anti-PD | 99.2 (95.4 to 100) | 97.9 (92.7 to 99.7) | 100 (95.1 to 100) | 100 (97 to 100) |
| Anti-PE | 100 (96.9 to 100) | 100 (96.2 to 100) | 100 (95.1 to 100) | 100 (97.1 to 100) |
| Anti-PilA | 100 (96.9 to 100) | 100 (96.2 to 100) | 100 (95.1 to 100) | 100 (97.1 to 100) |
| Anti-UspA2 | 100 (96.9 to 100) | 100 (96.2 to 100) | 100 (95.1 to 100) | 100 (97.1 to 100) |
Frequency of specific CD4+ T-cells was measured by flow cytometry intracellular cytokine staining (ICS) expressing at least 2 different markers among CD40 Ligand (CD40L), interleukin (IL)-2, IL-13, IL-17, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), upon in vitro stimulation
| CD4+ T cells/million cells | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| M catarrhalis.UspA2 - CD4+ T-cells | 112.945 ± 153.903 | 101.739 ± 94.932 | 81.578 ± 90.919 | 92.685 ± 99.661 |
| NTHi.PD - CD4+ T-cells | 89.456 ± 68.929 | 59.522 ± 82.06 | 36.439 ± 57.347 | 96.893 ± 74.87 |
| NTHi.PE - CD4+ T-cells | 79.838 ± 58.999 | 46.112 ± 63.007 | 69.546 ± 97.09 | 80.717 ± 119.316 |
| NTHi.PilA - CD4+ T-cells | 61.627 ± 53.613 | 42.438 ± 55.575 | 60.139 ± 51.37 | 105.558 ± 97.618 |
Frequency of specific CD4+ T-cells was measured by flow cytometry ICS expressing at least 2 different markers among CD40L, IL-2, IL-13, IL-17, TNF-α and IFN-γ, upon in vitro stimulation
| CD4+ T cells/million cells | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| M catarrhalis.UspA2 - CD4+ T-cells | 721.851 ± 457.94 | 619.68 ± 392.133 | 1001.839 ± 144.057 | 735.177 ± 471.515 |
| NTHi.PD - CD4+ T-cells | 632.849 ± 323.731 | 527.26 ± 281.827 | 1570.631 ± 1064.327 | 742.666 ± 527.567 |
| NTHi.PE - CD4+ T-cells | 565.964 ± 411.715 | 581.338 ± 520.594 | 888.057 ± 154.524 | 1155.341 ± 699.841 |
| NTHi.PilA - CD4+ T-cells | 332.43 ± 273.215 | 318.46 ± 195.527 | 333.501 ± 121.712 | 388.282 ± 207.434 |
The percentage of subjects with at least one local solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed local symptoms were pain, redness and swelling. Any local injection site redness/swelling is scored as follows: diameter \>=20 milli-meters
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| Erythema (mm), Dose 1 | 6 (2.6 to 11.4) | 15 (9.4 to 22.3) | 11 (6 to 18.1) | 12.6 (7.5 to 19.4) |
| Erythema (mm), Dose 2 | 12.8 (7.6 to 19.7) | 13.7 (8.4 to 20.8) | 17.9 (11.5 to 26.1) | 11.8 (6.8 to 18.7) |
| Pain, Dose 1 | 59.7 (50.9 to 68.1) | 69.2 (60.6 to 76.9) | 61 (51.6 to 69.9) | 63.7 (55 to 71.8) |
| Pain, Dose 2 | 69.9 (61.4 to 77.6) | 76.3 (68.1 to 83.3) | 72.6 (63.6 to 80.5) | 75.6 (67.2 to 82.8) |
| Swelling (mm), Dose 1 | 3.7 (1.2 to 8.5) | 10.5 (5.9 to 17) | 5.9 (2.4 to 11.8) | 5.2 (2.1 to 10.4) |
| Swelling (mm), Dose 2 | 7.5 (3.7 to 13.4) | 8.4 (4.3 to 14.5) | 6.8 (3 to 13) | 7.9 (3.8 to 14) |
The percentage of subjects with at least one general solicited AE, regardless of intensity, during the 7-day follow-up period after each NTHi-Mcat vaccine dose, are reported by study group. Assessed solicited general symptoms were Fatigue, Gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Chills and Fever (oral cavity or axillary route - temperature equal or higher than \[\>=\] 37.5 degrees Celsius \[°C\])
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| Chills, Dose 1 | 11.9 (7 to 18.7) | 12 (7 to 18.8) | 16.9 (10.7 to 25) | 7.4 (3.6 to 13.2) |
| Chills, Dose 2 | 25.6 (18.4 to 33.8) | 26 (18.7 to 34.3) | 22.2 (15.1 to 30.8) | 16.5 (10.5 to 24.2) |
| Fatigue, Dose 1 | 26.1 (18.9 to 34.4) | 38.3 (30.1 to 47.2) | 39 (30.1 to 48.4) | 34.1 (26.1 to 42.7) |
| Fatigue, Dose 2 | 39.1 (30.8 to 47.9) | 48.1 (39.3 to 57) | 43.6 (34.4 to 53.1) | 37.8 (29.3 to 46.8) |
| Fever (C), Dose 1 | 1.5 (0.2 to 5.3) | 1.5 (0.2 to 5.3) | 2.5 (0.5 to 7.3) | 3 (0.8 to 7.4) |
| Fever (C), Dose 2 | 11.3 (6.5 to 17.9) | 8.4 (4.3 to 14.5) | 8.5 (4.2 to 15.2) | 8.7 (4.4 to 15) |
| Gastrointestinal symptoms, Dose 1 | 13.4 (8.2 to 20.4) | 13.5 (8.2 to 20.5) | 16.1 (10 to 24) | 13.3 (8.1 to 20.3) |
| Gastrointestinal symptoms, Dose 2 | 15.8 (10 to 23.1) | 15.3 (9.6 to 22.6) | 12.8 (7.4 to 20.3) | 9.4 (5 to 15.9) |
| Headache, Dose 1 | 20.9 (14.4 to 28.8) | 26.3 (19.1 to 34.7) | 22.9 (15.7 to 31.5) | 18.5 (12.4 to 26.1) |
| Headache, Dose 2 | 32.3 (24.5 to 41) | 38.2 (29.8 to 47.1) | 23.9 (16.5 to 32.7) | 22 (15.2 to 30.3) |
| Myalgia, Dose 1 | 20.1 (13.7 to 27.9) | 23.3 (16.4 to 31.4) | 25.4 (17.9 to 34.3) | 27.4 (20.1 to 35.7) |
| Myalgia, Dose 2 | 33.1 (25.2 to 41.8) | 37.4 (29.1 to 46.3) | 36.8 (28 to 46.2) | 37.8 (29.3 to 46.8) |
An unsolicited adverse event is an adverse event that was not solicited using a Subject Diary and that was spontaneously communicated by a subject who has signed the informed consent. The percentage of subjects with at least one unsolicited AE, regardless of intensity or relationship to vaccination, during the 30-day follow-up period after any NTHi-Mcat vaccine dose are reported for each group. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group |
|---|---|---|---|---|
| Dose 1 | 13.4 (8.2 to 20.4) | 14.9 (9.4 to 22.1) | 11.5 (6.4 to 18.5) | 18.5 (12.4 to 26.1) |
| Dose 2 | 15 (9.4 to 22.3) | 15.3 (9.6 to 22.6) | 8.5 (4.1 to 15) | 10.9 (6.1 to 17.5) |
The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 1 up to and including Day 331, were reported for each group An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group |
|---|---|---|---|---|---|
| Percentage of Subjects With Any Serious Adverse Event (SAE) During Epoch 001 | 4.5 (1.7 to 9.5) | 3.7 (1.2 to 8.5) | 2.5 (0.5 to 7) | 1.5 (0.2 to 5.2) | 6.3 (0.2 to 30.2) |
pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group |
|---|---|---|---|---|---|
| Percentage of Subjects With Any Potential Immune-mediated Diseases (pIMD's) During Epoch 001 | 0 (0 to 2.7) | 1.5 (0.2 to 5.3) | 0.8 (0 to 4.5) | 0 (0 to 2.7) | 12.5 (1.6 to 38.3) |
The percentage of subjects with at least one SAE, regardless of intensity or relationship to vaccination, from Day 332 up to and including Day 661, are reported for each group. An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, requires hospitalization or prolongation of hospitalization, resulted in disability/incapacity in a subject or was a congenital anomaly/birth defect in the offspring of a study subject. AE(s) considered as SAE(s) also include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, as per the medical or scientific judgement of the physician.
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group |
|---|---|---|---|---|---|
| Percentage of Subjects With Any SAE During Epoch 002 | 3.0 (0.8 to 7.5) | 4.5 (1.7 to 9.5) | 3.3 (0.9 to 8.2) | 2.2 (0.5 to 6.4) | 0.0 (0.0 to 20.6) |
pIMD's are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology
| Percentage of subjects | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group |
|---|---|---|---|---|---|
| Percentage of Subjects With Any pIMD's During Epoch 002 | 0.7 (0.0 to 4.1) | 0.7 (0.0 to 4.1) | 0.0 (0.0 to 3.0) | 0.0 (0.0 to 2.7) | 0.0 (0.0 to 20.6) |
Collected over Solicited adverse events were collected during the 7-day follow-up period and unsolicited adverse events during the 30-day follow-up period. Serious adverse events were collected from Day 1 up to Day 661.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sh_NTHi-Mcat_1 Group | 0/134 (0%) | 9/134 (6.7%) | 118/134 (88.1%) |
| Sh_NTHi-Mcat_3 Group | 1/134 (0.7%) | 11/134 (8.2%) | 125/134 (93.3%) |
| Sh_NTHi-Mcat_6 Group | 0/122 (0%) | 6/122 (4.9%) | 107/122 (87.7%) |
| NTHi-Mcat Group | 0/135 (0%) | 5/135 (3.7%) | 125/135 (92.6%) |
| Shingrix-Only Group | 0/16 (0%) | 1/16 (6.3%) | — |
| Event | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group |
|---|---|---|---|---|---|
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/134 | 0/134 | 0/122 | 0/135 | 1/16 |
| Atrial fibrillationCardiac disorders | 0/134 | 0/134 | 2/122 | 0/135 | 0/16 |
| LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/134 | 2/134 | 0/122 | 0/135 | 0/16 |
| COVID-19Infections and infestations | 0/134 | 0/134 | 1/122 | 0/135 | 0/16 |
| Acute myocardial infarctionCardiac disorders | 1/134 | 0/134 | 1/122 | 0/135 | 0/16 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/134 | 1/134 | 1/122 | 0/135 | 0/16 |
| Cardiac failureCardiac disorders | 0/134 | 0/134 | 1/122 | 0/135 | 0/16 |
| Tendon disorderMusculoskeletal and connective tissue disorders | 0/134 | 0/134 | 1/122 | 0/135 | 0/16 |
| Embolism venousVascular disorders | 0/134 | 0/134 | 1/122 | 0/135 | 0/16 |
| Calculus urinaryRenal and urinary disorders | 0/134 | 0/134 | 1/122 | 0/135 | 0/16 |
| Event | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 105/134 | 112/134 | 98/122 | 112/135 | — |
| FatigueGeneral disorders | 63/134 | 78/134 | 68/122 | 65/135 | — |
| MyalgiaMusculoskeletal and connective tissue disorders | 48/134 | 64/134 | 56/122 | 67/135 | — |
| HeadacheNervous system disorders | 56/134 | 66/134 | 44/122 | 42/135 | — |
| ChillsGeneral disorders | 40/134 | 41/134 | 40/122 | 26/135 | — |
| Gastrointestinal disorderGastrointestinal disorders | 34/134 | 32/134 | 26/122 | 26/135 | — |
| Injection site erythemaGeneral disorders | 21/134 | 27/134 | 28/122 | 24/135 | — |
| Injection site swellingGeneral disorders | 12/134 | 19/134 | 13/122 | 15/135 | — |
| PyrexiaGeneral disorders | 16/134 | 12/134 | 13/122 | 14/135 | — |
| GastritisGastrointestinal disorders | 0/134 | 3/134 | 0/122 | 0/135 | — |
| Age, Continuous(Years) | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group | Total |
|---|---|---|---|---|---|---|
| Mean | 60.7 ± 7.0 | 60.9 ± 6.7 | 60.5 ± 7.1 | 60.0 ± 7.1 | 62.4 ± 5.5 | 60.6 ± 6.9 |
| Sex: Female, Male(Participants) | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group | Total |
|---|---|---|---|---|---|---|
| Female | 63 | 66 | 58 | 65 | 7 | 259 |
| Male | 71 | 68 | 64 | 70 | 9 | 282 |
| Race/Ethnicity, Customized(Participants) | Sh_NTHi-Mcat_1 Group | Sh_NTHi-Mcat_3 Group | Sh_NTHi-Mcat_6 Group | NTHi-Mcat Group | Shingrix-Only Group | Total |
|---|---|---|---|---|---|---|
| American Indian Or Alaska Native | 1 | 0 | 0 | 1 | 0 | 2 |
| Black Or African American | 0 | 1 | 0 | 1 | 0 | 2 |
| Not Reported | 0 | 0 | 0 | 0 | 1 | 1 |
| Other | 4 | 3 | 2 | 4 | 4 | 17 |
| White | 129 | 130 | 120 | 129 | 11 | 519 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Apr 2019 to primary completion in Aug 2020, 16 months.
Results were first posted in Sep 2021, 1 year after primary completion.
Of 12 phase 2 interventional studies under Respiration Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix